Drug Testing
Closeup of a Petri Dish
Pharmaceutical Machinery
3D Scans
Inpatient Drug Abuse Treatment

About Us

Revolutionizing CNS Treatments through Nanomedicine

MVK Pharmaceuticals is an early-stage drug development company that has completed positive preclinical trials and is in the process of submitting an IND package to the FDA to begin Phase I human studies.  The company seeks to advance a first-in-class treatment of suicidal ideation with major depression through intranasal delivery of a three amino acid neuropeptide loaded in a biodegradable nanoparticle. Success will launch a pipeline of drugs for various treatments that range from PTSD, TBI, anxiety, sleep, addictions, epilepsy, and other disorders.

 

Management Team

 

Michael Kubek, PhD

Founder and Chief Executive Officer

Abraham Domb, PhD

Founder and Chief Scientific Officer

Neal Naito, MD, MPH

Chief Medical Officer

Director of Business Development, and

Co-Founder

Christopher Browning, MBA

Chief Operating Officer and Co-Founder

Specialties Team

 

Tracy Glauser, MD

Director of Neurology

Alan Breier, MD

Director of Psychiatry

Stephen Byrn, PhD

Director of R&D and Manufacturing Operations

Clinical Trials

IND Submission for Phase I Human Trials

MVK Pharmaceuticals is preparing a FDA IND packet for the indication of Major Depression with Suicidal Ideation.  The company will request Fast Track designation and plans to submit in 2017.

 

R&D Pipeline

 

Major Depression with Suicide Ideation

Studies in 2013 by the CDC found that an estimated 9.3M adults aged 18 years and older in the US reported having suicidal thoughts. An estimated annual average of 2.7M adults in the US report having made suicide plans in the past year and 1.1M attempted.   Of those that attempted, 0.9M had plans and 0.2 did not and over 41,000 completed their suicide attempt.

We lose 22 veterans per day in the US and MVK Pharmaceuticals has elected to do something about it.  Through a DoD grant from 2012, clinical trials in patients with major depression  and suicidal ideation are planned to begin in 2017 to help with this growing epidemic in the DoD, VA, and civilian populations.   

PTSD

Within a given year, 8 million US adults develop post-traumatic stress disorder (PTSD) and an average between 7-8 people out of 100 will develop PTSD within their lifetime.  At the heart of PTSD is a traumatic event and for the military this means combat.  It is estimated that 11-20% of the OIF and OEF veterans, 12% of Gulf War veterans, and 15% of Vietnam veterans have PTSD in a given year,


MVK Pharmaceuticals is committed to advancing current treatments for PTSD hallmarked by anxiety, depression, drug and alcohol abuse, and sleep disorders. 

Infantile Spasms

Approximately 3,000 babies are born per year in the US with Infantile Spasms.  Infantile spasms are characterized by clusters of sudden contractions that occur up to 100 times per day that begin between 3 and 8 months and last until the child is 2 to 4 years old.  Current medications for infantile spasms have side effects that include: visual filed restriction, intellectual disability, and Cushing’s Syndrome, just to name a few.

MVK Pharmaceuticals intends to investigate compounds that are both clinically effective and allow the child to develop with reduced side effects.

MVK Pharmaceuticals in the Media

 

Can nasal spray help prevent military suicides?

Could the solution to increasing suicide and depression rates among members of the U.S. military lie in a nasal spray? The Army hopes so.

CURE Citizens United for Research in Epilepsy

Dr. Michael Kubek recieves the Rhode Island Award for 'Intranasal Delivery of Sustained-Release Anticonvulsant Neuropeptide Nanoparticles in Seizure Therapy'

Contact Us

Interested in our technology? Send us a message today.

 

Collaborations

 

CURE

1 in 26 Americans will develop epilepsy in their lifetime. 

65 million people worldwide desperately need a cure. 

CURE.png
CTSI.jpg

Indiana CTSI

The Indiana CTSI seeks to improve the health of individuals and communities by supporting highest-quality research and partnerships. We provide access to resources, services, training, education and funding opportunities.

ICBI

ICBI provides a platform to academic entrepreneurs for translation of their discoveries into commercial products for healthcare. ICBI will catalyze formation of new companies leading to significant economic and social impact.

ICBI.jpg

†Website Disclaimer

Our website has links to federal agencies and private organizations. You should be aware that:

  • This graphic notice, , means that you are leaving the MVK Pharmaceutical's site.

  • This external link provides additional information that is consistent with the intended purpose of the MVK Pharmaceuticals site.

  • MVK Pharmaceuticals cannot attest to the accuracy of information provided by this link.

  • Linking to any site does not constitute an endorsement by MVK Pharmaceuticals or any of its employees of the sponsors or the information and products presented on the site.

  • You will be subject to the destination site’s privacy policy when you leave the MVK Pharmaceutical's site.

 

Address

Noyes Pavilion, 5th Floor Suite E504, 1800 N Capitol Ave
Indianapolis, IN 46202
USA

Contact

317.374.2178

Follow

©2017 BY MVK PHARMACEUTICALS. PROUDLY CREATED WITH WIX.COM

Drug Testing